by Programme on International Nonproprietary Names (INN), Division of Drug Management & Policies, World Health Organization in Geneva .
Written in English
|Contributions||Programme on International Nonproprietary Names|
|LC Classifications||RS55 .G85 1997|
|The Physical Object|
|Pagination||iii, 36 p. :|
|Number of Pages||36|
The international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient. INNs make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since Guidelines on the use of International Nonproprietary Names (INNs) for pharmaceutical substances 1. General introduction The present guidelines on the use of International Nonproprietary Names (INNs) provide a general explanation of the INN selection process. They should be of interest to drug regulatory authorities for. An international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient.  INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors.  The INN system has been coordinated by the World Health Organization (WHO) . Under this naming convention, the nonproprietary name designated for each originator biological product, related biological product, and biosimilar product will be a proper name that is a.
International Nonproprietary Names (INN) facilitate the identification of pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. A nonproprietary name is also known as a generic name General guidance. Mandate. Guidance on the Use of International Nonproprietary Names (Inns) for Pharmaceutical Substances. Geneva: World Health Organization; Survey about International Nonproprietary Names (Inn): Level of Familiarity with the Inn Nomenclature System among Students, Academics, Scientists and Healthcare Practitioners. These nonproprietary (generic or proper) names refer to the unique active-ingredient component of the drug which can relate information about the chemical name or, in the case of the larger biological molecules, relate information about the nature of the complex molecule. 7 This is not the proprietary (brand) name that is trademarked or. International Nonproprietary Names. International Nonproprietary Names (INNs) constitute a nomenclature of over 8, generic names for pharmaceutical substances. Some examples are given in Table 2. They are designated by the World Health Organization (WHO) and formally placed in the public domain to promote consistency in global.
A list of the international nonproprietary names for pharmaceutical substances recommended by the World Health Organization (WHO) in is presented . fact that a trivial name has become accepted in the literature will not ensure its adoption as an INN, and may cause confusion when an official nonproprietary name is selected. The INN Guidelines therefore recommend applicants use codes before the publication of a recommended INN. International Nonproprietary Names (INN) 3 a monograph containing a nonproprietary name in the title that differs from that in the FDA license (e.g. a BLA proper name), it is possible. USP encourages FDA to pursue the idea of an orange book for biologics USP Perspective on Biosimilar Naming Drugs—The International Nonproprietary Name (INN). Most biologics, including vaccines, do not have INN or other generic names, so the brand name is used instead. Nonproprietary names are common nouns and hence should be lower case except in titles, the beginning of sentences, and in other situations that require capitalization.